ENDURANCE #mmsm most important findings
✅ No OS difference (2/3 of pts alive at 7 yrs follow up in both arms) and no meaningful PFS benefit (only 6% difference)
✅ Substantially more toxicity with continuous therapy
✅ Even in the arm assigned to continue indefinitely, only 14% of patients were still on treatment at the data-cutoff (nearly 12 years in), most stopped anyway, largely due to cumulative low-grade toxicity (fatigue, neuropathy, diarrhea) or disease progression
Time to move from "indefinite" maintenance in standard risk disease and with better available therapies hope we can even do shorter than 2 years I’d maintenance therapy @VincentRK@NEJM
🚨 New head-to-head RCT in @NEJM: apixaban vs rivaroxaban 🥊
🏆 Apixaban emerges as the safe winner, with half the risk of bleeding complications
💡 For patients at high risk of GI bleeding, apixaban may be preferrable to rivaroxaban
https://t.co/Drqxr1kDu4
Finally, we are moving the needle on the ferritin threshold for diagnosing iron deficiency.
#ASH25 Clinical Practice Guidelines on Diagnosis of Iron Deficiency
In adults who are not pregnant and not menstruating, please use a ferritin threshold of 30.
#ASHScavengerHunt
Thrilled to share that our abstract has been accepted for poster presentation at the 67th @ASH_hematology Annual Meeting this December in Orlando!
Excited to connect with colleagues and discuss #Hemophilia & #BenignHeme at #ASH2025.